Literature DB >> 24345896

Pretransplant CD8 T-cell response to IE-1 discriminates seropositive kidney recipients at risk of developing CMV infection posttransplant.

Maria Ovidia López-Oliva1, Virginia Martinez, Agueda Buitrago, Carlos Jiménez, Begoña Rivas, Fernando Escuin, María José Santana, Rafael Selgas, Teresa Bellón.   

Abstract

BACKGROUND: Cytomegalovirus (CMV) infection is an ongoing clinical problem in solid-organ transplantation (SOT). Pretransplant CMV serology is currently the only tool for assessing the risk of CMV infection, although cellular immune responses driven by CMV-specific CD4 and CD8 T lymphocytes are important for controlling viral replication. Therefore, the analysis of CMV-specific T cells may be useful for estimating the risk of infection.
METHODS: This is a prospective study of patients with kidney transplants and no prophylactic treatment for CMV replication. CD4 and CD8 T-cell responses to the major CMV pp65 and IE-1 antigens in 15 seropositive patients at intermediate risk of CMV infection were investigated, according to current algorithms. Intracellular flow cytometry was employed to determine IFN-γ production as a functional readout. The response was analyzed in pretransplant samples and prospectively at 1 and 6 months and at 1 year posttransplant.
RESULTS: It was observed that the CD8 responses to IE-1 antigen were practically absent pretransplant in patients who developed CMV infection posttransplant. Within the group of patients free of infection, CD8 responses to IE-1 were detected more frequently and were significantly higher (P=0.0083). In a receiver operating characteristics curve analysis (AUC=0.929; P=0.010; 95% CI: 0.078-1.0), low CD8 responses to IE-1 (≤0.05%) pretransplant predicted the development of CMV infection under the immunosuppressive regime after transplant with 100% specificity and 85.7% sensitivity.
CONCLUSIONS: Assessment of IE-1-specific CD8 T-cell frequencies pretransplant may be a useful tool for identifying seropositive SOT patients at risk of developing CMV infection posttransplant.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24345896     DOI: 10.1097/01.TP.0000438025.96334.eb

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

1.  The impact of donor viral replication at transplant on recipient infections posttransplant: a prospective study.

Authors:  Priya S Verghese; David O Schmeling; Jennifer A Knight; Arthur J Matas; Henry H Balfour
Journal:  Transplantation       Date:  2015-03       Impact factor: 4.939

Review 2.  Utility of Cytomegalovirus Cell-Mediated Immunity Assays in Solid Organ Transplantation.

Authors:  Victoria G Hall; Atul Humar; Deepali Kumar
Journal:  J Clin Microbiol       Date:  2022-05-11       Impact factor: 11.677

3.  QuantiFERON-Cytomegalovirus Assay for Prediction of Cytomegalovirus Viremia in Kidney Transplant Recipients: Study From High Cytomegalovirus Seroprevalence Country.

Authors:  Kritsada Pongsakornkullachart; Methee Chayakulkeeree; Attapong Vongwiwatana; Wannee Kantakamalakul; Peenida Skulratanasak; Pakpoom Phoompoung
Journal:  Front Cell Infect Microbiol       Date:  2022-05-12       Impact factor: 6.073

Review 4.  Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients?

Authors:  Estéfani García-Ríos; Marcos Nuévalos; Francisco J Mancebo; Pilar Pérez-Romero
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

Review 5.  Gut microbiota and allogeneic transplantation.

Authors:  Weilin Wang; Shaoyan Xu; Zhigang Ren; Jianwen Jiang; Shusen Zheng
Journal:  J Transl Med       Date:  2015-08-23       Impact factor: 5.531

6.  Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients.

Authors:  Hyeyoung Lee; Ki Hyun Park; Ji Hyeong Ryu; Ae-Ran Choi; Ji Hyun Yu; Jihyang Lim; Kyungja Han; Sang Il Kim; Chul Woo Yang; Byung Ha Chung; Eun-Jee Oh
Journal:  PLoS One       Date:  2017-12-12       Impact factor: 3.240

7.  Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.

Authors:  Dominika Deborska-Materkowska; Agnieszka Perkowska-Ptasinska; Anna Sadowska; Jolanta Gozdowska; Michał Ciszek; Marta Serwanska-Swietek; Piotr Domagala; Dorota Miszewska-Szyszkowska; Elzbieta Sitarek; Agnieszka Jozwik; Artur Kwiatkowski; Magdalena Durlik
Journal:  BMC Infect Dis       Date:  2018-04-16       Impact factor: 3.090

8.  Efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY): an open-label, randomised, non-inferiority clinical trial.

Authors:  Aurora Paez-Vega; Sara Cantisan; José Manuel Vaquero; Elisa Vidal; Antonio Luque-Pineda; María Ángeles Lobo-Acosta; Ana Belén Pérez; Rodrigo Alonso-Moralejo; David Iturbe; Victor Monforte; Isabel Otero-Gonzalez; Amparo Pastor; Piedad Ussetti; Julian Torre-Cisneros
Journal:  BMJ Open       Date:  2019-08-15       Impact factor: 2.692

Review 9.  Diagnosis and treatment for the early stage of cytomegalovirus infection during hematopoietic stem cell transplantation.

Authors:  Jiaqi Cui; Kui Zhao; Yanling Sun; Ruijuan Wen; Xiangzhong Zhang; Xudong Li; Bing Long
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.